Clinical Trial Update: Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial update of IVIG (Bioven) for COVID-19 with severe pneumonia shows completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Bioven (intravenous immunoglobulin)

Snippet

Sponsor: Biopharma Plasma LLC | Conditions: Covid19, Pneumonia | Phase 3 | Status: COMPLETED